TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it is completing a non-brokered private placement of class A multiple voting shares (“MVS”) at a price of $50 per MVS, for aggregate gross proceeds of up to $600 (the “Offering”). The Company expects that the entirety of the Offering ...

Core Insights - Quantum BioPharma Ltd. has engaged MZ Digital and Dealmaker to raise up to US$5 million through a Regulation D 506(c) offering for Unbuzzd Wellness Inc., which produces a beverage that accelerates alcohol metabolism and reduces hangover symptoms [1][2] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders [3] - Unbuzzd Wellness Inc. is a public issuer that offers a scientifically backed beverage designed to help alcohol consumers manage their consumption and recovery [5] Product Details - Unbuzzd is a proprietary blend of vitamins, minerals, and herbs that aids in faster alcohol metabolism, restores mental clarity, and improves cognition [5] - Clinical trials have shown that unbuzzd reduces blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, with significant improvements in alertness and reduced hangover symptoms [6][7][14] Financial Aspects - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to 7% royalty payments on sales until reaching $250 million, after which the royalty rate drops to 3% [3]

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™—the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms—is pleased to announce that it has enga ...

Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline ProgressJune 18, 2025 9:19 AM EDT | Source: Singular ResearchLos Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies, today released its analysis of Quantum BioPharma Ltd.'s (NASDAQ: QNTM) continued progress across its innovative pipeline of treatments for brain disorders and alcohol health.A link to the report is availab ...

Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302 TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that the first person with multiple sclerosis (MS) has been scanned in a joint study with Massachusetts ...

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce its intention to declare a special dividend consisting of Contingent Value Rights (the “CVRs”) to be issued on a 1:1 basis to holders of the Company’s Class B Subordinate Voting Shares. Each CVR will entitle the holder to receive a pro ra ...

The Company will continue to monitor market conditions and may increase or decrease its holdings of Bitcoin (BTC) or other cryptocurrencies as it deems appropriate. TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased additional Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. This bri ...

Core Viewpoint - Quantum BioPharma Ltd. addresses misinformation regarding its name and potential reverse takeover with Unbuzzd Wellness Inc., clarifying that it has not changed its name and is not involved in any RTO transaction with Unbuzzd [1][2] Company Overview - Quantum BioPharma is a biopharmaceutical company focused on innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [6] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc. as of March 31, 2025, and has developed the product unbuzzd™, which aids in alcohol metabolism [6] Financial Agreements - Quantum BioPharma is the largest shareholder and debt holder of Unbuzzd Wellness Inc., receiving a 7% royalty on revenue until a total of $250 million is paid, after which the rate drops to 3% [3] - Quantum BioPharma has issued 200 million common shares to Unbuzzd Wellness Inc. as a license fee and holds an anti-dilution warrant to increase its stake to 25% [3] - A loan agreement was established where Quantum loaned Unbuzzd Wellness Inc. $1.3 million at a 10% annual interest rate, secured for three years [3] Leadership and Expertise - Unbuzzd Wellness Inc. is led by CEO John Duffy, who has a strong background in the beverage industry, and is supported by Gerry David, former CEO of Celsius Holdings, Inc. [4] Product Information - Unbuzzd is a scientifically-backed product that accelerates alcohol metabolism and reduces hangover symptoms, supported by clinical trials [9] - The product is available in various formats and aims to appeal to consumers looking for responsible drinking solutions [8][9] Debt Settlement - Quantum BioPharma has authorized a debt settlement totaling USD $20,930 with Class B Shares, expected to be completed in early June 2025 [5]

TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), announced today that the Company and Dr. Raza Bokhari, Company’s former Executive Chairman and Chief Executive Officer (CEO), have reached a global settlement agreement (the “agreement”) to settle all and any disputes originating out of the proxy contest originally commencing January 2021. Mr. Zeeshan Saeed, Co-Chairman & CEO, and Mr. Anthony Durkacz, Co-Chairman of ...

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the “Company”), the company behind unbuzzdTM, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, that it has hired leading audit fi ...